Patents Assigned to Taisho Pharmaceutical Co., Ltd.
-
Patent number: 9499477Abstract: Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 21, 2015Date of Patent: November 22, 2016Assignees: TOYAMA CHEMICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTDInventors: Hajime Takashima, Risa Tsuruta, Tetsuya Yabuuchi, Yusuke Oka, Hiroki Urabe, Yoichiro Suga, Masato Takahashi, Fumito Uneuchi, Hironori Kotsubo, Muneo Shoji, Yasuko Kawaguchi
-
Publication number: 20160289208Abstract: This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior UK-activating effect and is useful as a pharmaceutical.Type: ApplicationFiled: November 12, 2013Publication date: October 6, 2016Applicants: TAISHO PHARMACEUTICAL CO., LTD., NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Shoichi KURODA, Yudai IMAI, Takanori KAWAGUCHI, Keiko FUSEGI, Masahiro BOHNO, Hajime ASANUMA, Tomomichi CHONAN, Nagaaki SATO, Souichi MONMA, Shigetada SASAKO, Marie MIZUTANI, Shin ITOH, Takumi OKADA, Hirofumi OTA, Seishi ISHIYAMA
-
Patent number: 9428483Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 31, 2013Date of Patent: August 30, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
-
Patent number: 9422240Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.Type: GrantFiled: July 29, 2013Date of Patent: August 23, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Tetsuo Takayama, Tsuyoshi Shibata, Fumiyasu Shiozawa, Kenichi Kawabe, Yuki Shimizu, Makoto Hamada, Akira Hiratate, Masato Takahashi, Fumihito Ushiyama, Takahiro Oi, Yoshihisa Shirasaki, Daisuke Matsuda, Chie Koizumi, Sota Kato
-
Publication number: 20160159814Abstract: The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.Type: ApplicationFiled: July 25, 2014Publication date: June 9, 2016Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Daisuki WAKASUGI, Hiroshi OHTA, Kumiko OKADA, Shin-ichi SHIROKAWA, Minoru MORIYA, Tomoko TAMITA, Kumi ABE, Nobutaka HATTORI, Yuko ARAKI
-
Publication number: 20160130278Abstract: The present invention provides novel compounds of formula [IA] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.Type: ApplicationFiled: June 9, 2014Publication date: May 12, 2016Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Yousuke YAMADA, Hiroshi OHTA, Tomoko TAMITA, Kumi ABE, Shuji YAMAMOTO, Shin-ichi SHIROKAWA, Masahito ABE, Yohei MATSUDA, Yuko ARAKI
-
Patent number: 9320727Abstract: Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.Type: GrantFiled: August 30, 2013Date of Patent: April 26, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Naoki Kojima, Richard J. Roman, Noriyuki Miyata, Teisuke Takahashi, Hideki Tomoike, Takuya Takeda
-
Publication number: 20160095848Abstract: Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds.Type: ApplicationFiled: December 11, 2015Publication date: April 7, 2016Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Toshio NAKAMURA, Seiji MASUDA
-
Patent number: 9284324Abstract: Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds.Type: GrantFiled: December 7, 2012Date of Patent: March 15, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Toshio Nakamura, Seiji Masuda
-
Patent number: 9266870Abstract: A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.Type: GrantFiled: June 13, 2013Date of Patent: February 23, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Aya Futamura, Yuko Araki, Masahito Abe, Hiroshi Ohta, Ryo Suzuki, Dai Nozawa
-
Publication number: 20150374735Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:Type: ApplicationFiled: February 3, 2014Publication date: December 31, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Daisuke YAMAMOTO, Fusayo IO, Koji YAMAMOTO
-
Publication number: 20150343009Abstract: An orally administered liquid formulation, characterized by being obtained by blending a) vitamin B2 or an orally administrable sale thereof, b) an herbal-medicine-derived component, c) 1-10 parts by mass of polyvinyl pyrrolidone with respect to 1 part by mass (raw herbal medicine amount) of the herbal-medicine-derived component, and d) 0.02-1.6 parts by mass of at least one species selected from gallic acid and a derivative thereof with respect to 1 part by mass of vitamin B2. This orally administered liquid formulation has the excellent stability of a vitamin B2 species and does not precipitate in a liquid formulation, and can be applied in the fields of medicine and food products.Type: ApplicationFiled: November 13, 2013Publication date: December 3, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Takanori IGARASHI, Masaru HATANAKA, Masashi YAMAMOTO, Keisuke NAKAMOTO
-
Patent number: 9193695Abstract: The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.Type: GrantFiled: September 30, 2011Date of Patent: November 24, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takeshi Kuwada, Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki, Naoki Miyakoshi
-
Publication number: 20150327585Abstract: An aqueous carbonated beverage comprises any one of: 0.01 w/v % or more of a LM pectin; 0.1 w/v % or more of alginic acid or a salt thereof; and 0.001 w/v % or more of gellan gum, wherein the aqueous carbonated beverage has a pH of 3.5 to 7.0.Type: ApplicationFiled: December 12, 2013Publication date: November 19, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takashi DOMOTO, Marie YAMAJI, Akane SAKATA
-
Publication number: 20150320721Abstract: Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function.Type: ApplicationFiled: August 30, 2013Publication date: November 12, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTDInventors: Naoki KOJIMA, Richard J. ROMAN, Noriyuki MIYATA, Teisuke TAKAHASHI, Hideki TOMOIKE, Takuya TAKEDA
-
Patent number: 9181229Abstract: Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where R1 represents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.Type: GrantFiled: March 15, 2012Date of Patent: November 10, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Naoya Ono, Shoichi Kuroda, Yoshihisa Shirasaki, Tetsuo Takayama, Yoshinori Sekiguchi, Fumihito Ushiyama, Yusuke Oka
-
Patent number: 9161945Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.Type: GrantFiled: August 19, 2011Date of Patent: October 20, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Fumiyasu Shiozawa, Yuki Iwata, Takahiro Oi, Kenichi Kawabe
-
Patent number: 9139609Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).Type: GrantFiled: February 20, 2012Date of Patent: September 22, 2015Assignees: TAISHO PHARMACEUTICAL CO., LTD., MEIJI SEIKA PHARMA CO., LTD.Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
-
Publication number: 20150225335Abstract: Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria.Type: ApplicationFiled: April 21, 2015Publication date: August 13, 2015Applicants: TAISHO PHARMACEUTICAL CO., LTD., TOYAMA CHEMICAL CO., LTD.Inventors: Hajime TAKASHIMA, Risa TSURUTA, Tetsuya YABUUCHI, Yusuke OKA, Hiroki URABE, Yoichiro SUGA, Masato TAKAHASHI, Fumito UNEUCHI, Hironori KOTSUBO, Muneo SHOJI, Yasuko KAWAGUCHI
-
Patent number: 9101588Abstract: A composition for lowering a blood uric acid level is characterized by comprising taurine as an active ingredient.Type: GrantFiled: September 10, 2010Date of Patent: August 11, 2015Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Fuminori Kimura, Hideaki Kitajima, Takao Tanaka, Toru Nishikawa